Progress in Clinical Neurosciences A Systematic Review of the Use of Triptans in Acute Migraine
| Autor: | Marek Gawel, Irene Worthington, Anne Maggisano |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Gynecology
medicine.medical_specialty Acute migraine Naratriptan business.industry General Medicine Triptans 030226 pharmacology & pharmacy Rizatriptan 03 medical and health sciences 0302 clinical medicine Neurology Anesthesia medicine Neurology (clinical) business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 28:30-41 |
| ISSN: | 2057-0155 0317-1671 |
| DOI: | 10.1017/s0317167100052525 |
| Popis: | Objective:A systematic review of the literature was undertaken, to consolidate evidence concerning the efficacy and safety of triptans currently available in Canada (sumatriptan, rizatriptan, naratriptan, zolmitriptan), and to provide guidelines for selection of a triptan.Methods:Data from published, randomized, placebo-controlled trials were pooled and a combined number needed to treat (NNT) and number needed to harm (NNH) was generated for each triptan. Direct comparative trials of triptans were also examined.Results:The lowest NNTfor headache response/pain-free at one/two hours is observed with subcutaneous sumatriptan. Among the oral formulations, the lowest NNT is observed with rizatriptan and the highest NENT with naratriptan. The lowest NNH is observed with subcutaneous sumatriptan.Conclusions:Triptans are relatively safe and effective medications for acute migraine attacks. However, differences among them are relatively small. Considerations in selecting a triptan include individual patient response/tolerance, characteristics of the attacks, relief of associated symptoms, consistency of response, headache recurrence, delivery systems and patient preference. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|